Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC 5013 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| CC-5013 | DRUG | - |
| CC 5013 | DRUG | - |
* Understand and voluntarily sign an informed consent form * Able to adhere to the study visit schedule and other protocol requirements * Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy * Women of childbearing potential must have a negative serum or ...
Top 20 of 51 competitors
CC 5013 is an investigational small molecule being studied for multiple conditions including Crohn's Disease, Myelodysplastic Syndromes, Melanoma, Non-Small Cell Lung Cancer, and Multiple Myeloma. It is in Phase 3 clinical development for these indications, though it remains investigational and is not yet approved.
CC 5013 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials of this small molecule across several oncology and inflammatory disease indications.
CC 5013 is in Phase 3 clinical development. It has completed six clinical trials with a total enrollment of 1,433 participants. The drug is investigational and has not been approved by regulatory authorities for any indication.
CC 5013 has completed six clinical trials, including NCT00051116, NCT00065351, NCT00091624, and NCT00424047. These trials studied the drug in multiple myeloma, with the Phase 3 trial NCT00424047 comparing CC 5013 plus dexamethasone versus dexamethasone alone in previously treated patients.
CC 5013 is an investigational small molecule being developed by Bristol-Myers Squibb. It is being studied in multiple myeloma and other conditions. The drug has completed Phase 3 trials but remains in clinical development and is not approved.